UA113963C2 - Антагоністи trpv4 - Google Patents

Антагоністи trpv4 Download PDF

Info

Publication number
UA113963C2
UA113963C2 UAA201400152A UAA201400152A UA113963C2 UA 113963 C2 UA113963 C2 UA 113963C2 UA A201400152 A UAA201400152 A UA A201400152A UA A201400152 A UAA201400152 A UA A201400152A UA 113963 C2 UA113963 C2 UA 113963C2
Authority
UA
Ukraine
Prior art keywords
methyl
carbonitrile
oxa
oxo
azaspiro
Prior art date
Application number
UAA201400152A
Other languages
English (en)
Ukrainian (uk)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47558389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA113963(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of UA113963C2 publication Critical patent/UA113963C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D419/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
UAA201400152A 2011-06-17 2012-06-15 Антагоністи trpv4 UA113963C2 (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161498110P 2011-06-17 2011-06-17
PCT/US2012/042622 WO2013012500A1 (en) 2011-06-17 2012-06-15 Trpv4 antagonists

Publications (1)

Publication Number Publication Date
UA113963C2 true UA113963C2 (xx) 2017-04-10

Family

ID=47558389

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201400152A UA113963C2 (xx) 2011-06-17 2012-06-15 Антагоністи trpv4

Country Status (38)

Country Link
US (1) US9187464B2 (https=)
EP (2) EP2721016B1 (https=)
JP (1) JP5969017B2 (https=)
KR (1) KR101870003B1 (https=)
CN (1) CN103732583B (https=)
AR (1) AR086958A1 (https=)
AU (1) AU2012284540B2 (https=)
BR (1) BR112013032391B1 (https=)
CA (1) CA2839743C (https=)
CL (1) CL2013003602A1 (https=)
CO (1) CO6821953A2 (https=)
CR (1) CR20130671A (https=)
CY (1) CY1117792T1 (https=)
DK (1) DK2721016T3 (https=)
DO (1) DOP2013000307A (https=)
EA (1) EA023616B1 (https=)
ES (2) ES2569193T3 (https=)
HR (1) HRP20160539T1 (https=)
HU (1) HUE029594T2 (https=)
IL (1) IL229872A (https=)
JO (1) JO3154B1 (https=)
MA (1) MA35184B1 (https=)
ME (1) ME02416B (https=)
MX (1) MX337440B (https=)
MY (1) MY173521A (https=)
PE (1) PE20141943A1 (https=)
PH (1) PH12013502463A1 (https=)
PL (1) PL2721016T3 (https=)
PT (1) PT2721016E (https=)
RS (1) RS54858B1 (https=)
SG (1) SG195106A1 (https=)
SI (1) SI2721016T1 (https=)
SM (1) SMT201600150B (https=)
TW (1) TWI538912B (https=)
UA (1) UA113963C2 (https=)
UY (1) UY34138A (https=)
WO (1) WO2013012500A1 (https=)
ZA (1) ZA201308816B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2595606T3 (es) * 2011-06-17 2017-01-02 Glaxosmithkline Intellectual Property (No. 2) Limited Antagonistas TRPV4
ES2571409T3 (es) 2011-06-17 2016-05-25 Glaxosmithkline Intellectual Property (No 2) Ltd Antagonistas espiro-cíclicos de TRPV4
EP2832731A4 (en) 2012-03-27 2015-08-19 Shionogi & Co AROMATIC HETEROCYCLIC CHAIN 5-CORE DERIVED DERIVATIVE HAVING TRPV4 INHIBITORY ACTIVITY
WO2015046193A1 (ja) 2013-09-25 2015-04-02 塩野義製薬株式会社 Trpv4阻害活性を有する芳香族複素環式アミン誘導体
WO2017199199A1 (en) 2016-05-19 2017-11-23 Glaxosmithkline Intellectual Property (No.2) Limited Trpv4 antagonist
US10968209B2 (en) 2016-05-19 2021-04-06 Glaxosmithkline Intellectual Property (No.2) Limited TRPV4 antagonist
CN115626935B (zh) 2016-10-03 2025-07-15 詹森药业有限公司 用作prmt5抑制剂的单环和双环系统取代的卡巴核苷类似物
WO2018185701A1 (en) 2017-04-06 2018-10-11 Glaxosmithkline Intellectual Property (No.2) Limited Trpv4 antagonists as antitussive agents
KR102731924B1 (ko) * 2017-11-01 2024-11-19 브리스톨-마이어스 스큅 컴퍼니 파르네소이드 x 수용체 조정제로서의 스피로시클릭 화합물
WO2021170811A1 (en) 2020-02-27 2021-09-02 Glaxosmithkline Intellectual Property (No.2) Limited Method of treating eye disease using trpv4 antagonists
WO2021221169A1 (en) 2020-04-30 2021-11-04 Raqualia Pharma Inc. Pyrimidin-4(3h)-one derivatives as trpv4 antagonists
CN111704613B (zh) * 2020-06-23 2021-07-06 中国人民解放军军事科学院军事医学研究院 咪唑类衍生物及其作为trpv4抑制剂的用途
KR20230041680A (ko) * 2020-07-16 2023-03-24 라퀄리아 파마 인코포레이티드 안구 질환 치료제로서의 trpv4 억제제
CA3261160A1 (en) 2022-07-08 2024-01-11 Actio Biosciences, Inc. COMPOUNDS AND THERAPEUTIC METHODS
WO2024217429A1 (zh) * 2023-04-18 2024-10-24 河北乌图药业有限公司 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用
CN120225516A (zh) * 2023-04-18 2025-06-27 河北乌图药业有限公司 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用
CN120641413A (zh) * 2023-04-18 2025-09-12 河北乌图药业有限公司 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用
WO2024217452A1 (zh) * 2023-04-18 2024-10-24 河北乌图药业有限公司 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用
CN121175303A (zh) * 2023-04-18 2025-12-19 河北乌图药业有限公司 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用
CN121511242A (zh) * 2023-07-07 2026-02-10 爱克堤欧生物科学股份有限公司 Trpv4拮抗剂的固体形式
CN117945917A (zh) * 2023-12-26 2024-04-30 衢州康鹏化学有限公司 一种3-氟-4-硝基苯甲酸的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE482945T1 (de) * 1998-05-26 2010-10-15 Chugai Pharmaceutical Co Ltd Heterozyklische indolderivate und mono- oder diazaindol-derivate
CA2531619A1 (en) * 2003-07-16 2005-01-27 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
WO2007059608A1 (en) * 2005-11-23 2007-05-31 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
WO2007067756A2 (en) 2005-12-08 2007-06-14 Amphora Discovery Corporation Certain chemical entities, compositions, and methods for modulating trpv1
JP5858557B2 (ja) * 2005-12-22 2016-02-10 ハイドラ バイオサイエンシズ インコーポレイテッドHydra Biosciences,Inc. 疼痛を処置するためのtrpa1阻害剤
TW200819457A (en) * 2006-08-30 2008-05-01 Actelion Pharmaceuticals Ltd Spiro antibiotic derivatives
JP2010517967A (ja) * 2007-02-01 2010-05-27 グラクソ グループ リミテッド 摂食障害の治療のための1−オキサ−3−アザスピロ[4,5]デカン−2−オン誘導体
GB0707934D0 (en) * 2007-04-24 2007-05-30 Glaxo Group Ltd Chemical compounds
US7998982B2 (en) * 2007-08-09 2011-08-16 Abbott Laboratories Amide derivatives as TRPV1 antagonists
TW200944520A (en) * 2008-01-29 2009-11-01 Glaxo Group Ltd Spiro compounds as NPY Y5 receptor antagonists
JP5607046B2 (ja) * 2008-07-25 2014-10-15 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Trpv4拮抗薬
JP2012006837A (ja) * 2008-09-30 2012-01-12 Mochida Pharmaceut Co Ltd 2−インドールアクリルアミド類縁体
US8742110B2 (en) * 2010-08-18 2014-06-03 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
ES2571409T3 (es) * 2011-06-17 2016-05-25 Glaxosmithkline Intellectual Property (No 2) Ltd Antagonistas espiro-cíclicos de TRPV4
ES2595606T3 (es) * 2011-06-17 2017-01-02 Glaxosmithkline Intellectual Property (No. 2) Limited Antagonistas TRPV4

Also Published As

Publication number Publication date
PT2721016E (pt) 2016-06-06
CL2013003602A1 (es) 2014-07-04
EP2721016A4 (en) 2014-10-08
HK1195068A1 (zh) 2014-10-31
MX2013014898A (es) 2014-03-21
IL229872A (en) 2017-03-30
MX337440B (es) 2016-03-03
EA201490037A1 (ru) 2015-12-30
CY1117792T1 (el) 2017-05-17
TWI538912B (zh) 2016-06-21
BR112013032391B1 (pt) 2020-11-24
MA35184B1 (fr) 2014-06-02
WO2013012500A1 (en) 2013-01-24
HRP20160539T1 (hr) 2016-06-17
CN103732583A (zh) 2014-04-16
TW201313705A (zh) 2013-04-01
PH12013502463A1 (en) 2014-01-20
AU2012284540A1 (en) 2013-04-04
PL2721016T3 (pl) 2017-01-31
SMT201600150B (it) 2016-07-01
SG195106A1 (en) 2013-12-30
JP5969017B2 (ja) 2016-08-10
ES2569193T3 (es) 2016-05-09
EP2721016A1 (en) 2014-04-23
CN103732583B (zh) 2015-12-23
EP3121177B1 (en) 2018-08-01
AU2012284540B2 (en) 2014-08-28
US9187464B2 (en) 2015-11-17
SI2721016T1 (sl) 2016-06-30
EA023616B1 (ru) 2016-06-30
NZ618221A (en) 2015-02-27
CA2839743A1 (en) 2013-01-24
JP2014518214A (ja) 2014-07-28
MY173521A (en) 2020-01-30
EP2721016B1 (en) 2016-04-06
PE20141943A1 (es) 2014-12-28
KR20140041733A (ko) 2014-04-04
CR20130671A (es) 2014-02-04
BR112013032391A2 (pt) 2016-08-16
KR101870003B1 (ko) 2018-06-22
US20140121206A1 (en) 2014-05-01
EP3121177A1 (en) 2017-01-25
CA2839743C (en) 2017-03-28
UY34138A (es) 2013-01-03
AR086958A1 (es) 2014-02-05
DK2721016T3 (en) 2016-06-06
CO6821953A2 (es) 2013-12-31
ZA201308816B (en) 2015-02-25
ME02416B (me) 2016-09-20
RS54858B1 (sr) 2016-10-31
HUE029594T2 (en) 2017-03-28
ES2688733T3 (es) 2018-11-06
JO3154B1 (ar) 2017-09-20
DOP2013000307A (es) 2014-06-01

Similar Documents

Publication Publication Date Title
UA113963C2 (xx) Антагоністи trpv4
AU2018392321B2 (en) Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
CA3183097A1 (en) Lpa receptor antagonists and uses thereof
JP5969016B2 (ja) Trpv4拮抗薬
CA3133753A1 (en) Novel small molecule inhibitors of tead transcription factors
CA3158743A1 (en) Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof
UA123785C2 (uk) Сполуки піролотриазину як інгібітори tam
KR20150036481A (ko) 보체 경로 조절제 및 그의 용도
JP5969015B2 (ja) Trpv4拮抗薬
CA3218569A1 (en) Lpa receptor antagonists and uses thereof
JP2015523350A (ja) Rsウイルス抗ウイルス薬としての、ベンゾイミダゾールによって置換された新規1,3−ジヒドロ−2h−ベンゾイミダゾル−2−オン誘導体
CA2876993A1 (en) Pyrrolidine derivatives and their use as complement pathway modulators
TW202302537A (zh) Lpa受體拮抗劑及其用途
CA3121199A1 (en) Diarylhydantoin compounds and methods of use thereof
CA3171776A1 (en) Tricyclic compounds as egfr inhibitors
JP6885962B2 (ja) 1,4−ジカルボニル−ピペリジル誘導体
WO2019189555A1 (ja) 複素環化合物
UA122084C2 (uk) Похідні піролідину як інгібітори катепсинової протеази s
CA2991572A1 (en) 6-amino-quinoline-3-carbonitrils as cot modulators
HK1195068B (en) Trpv4 antagonists
NZ618221B2 (en) Trpv4 antagonists